The CC chemokine CKβ-11/MIP-3β/ELC/exodus 3 mediates tumor rejection of murine breast cancer cells through NK cells

Journal of Immunology

Volumn 164, Issue 8, 2000, Pages 4025-4031

  Braun, Stephen E ^a,b,c   Chen, Keyue ^a   Foster, Richard G ^a,b   Kim, Chang H ^a,b   Hromas, Robert ^a,b   Kaplan, Mark H ^a,b   Broxmeyer, Hal E ^a,b   Cornetta, Kenneth ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WALTHER CANCER INSTITUTE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CHEMOKINE; CHEMOKINE CKBETA 11; GANGLIOSIDE ANTIBODY; OKT 4; UNCLASSIFIED DRUG; VIRUS MESSENGER RNA; VIRUS VECTOR;

ADOPTIVE IMMUNOTHERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CARCINOMA; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CHEMOTAXIS; CONTROLLED STUDY; FEMALE; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; LYMPHOCYTE DEPLETION; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPLEEN CELL; T LYMPHOCYTE SUBPOPULATION; TUMOR REJECTION;

EID: 0034655163     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.164.8.4025     Document Type: Article

References (56)

1. Wingo, P., T. Tong, and S. Bolden. 1995. Cancer statistics. Cancer J. Clin. 45:8.
2. Fisher, B., C. Redmond, R. Poisson, R. Margolese, N. Wolmark, L. Wickerham, E. Fisher, M. Deutsch, R. Caplan, Y. Pilch, et al. 1989. Five year results of a randomized clinical trial comparing total mastectomy and segmental mastectomy and lymphectomy with or without irradiation in the treatment of breast cancer. N. Engl. J. Med. 320:822.
3. Gradishar, W. J., M. S. Tallman, and J. S. Abrams. 1996. High dose chemotherapy for breast cancer. Ann. Intern. Med. 125:599.
4. Wood, W. C., D. R. Budman, A. H. Korzun, M. R. Cooper, J. Younger, R. D. Hart, A. Moore, J. A. Ellerton, L. Norton, C. R. Ferree, et al. 1994. Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast cancer. N. Engl. J. Med. 330:1253.
5. Dranoff, G., E. Jaffee, A. Lazenby, P. Golumbek, H. Levitsky, K. Brose, V. Jackson, H. Hamada, D. Pardoll, and R. C. Mulligan. 1993. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci. USA 90:3539.
6. Chen, K., S. Braun, S. Lyman, Y. Fan, C. M. Traycoff, E. A. Wiebke, J. Gaddy, G. Sledge, H. E. Broxmeyer, and K. Cornetta. 1997. Antitumor activity and immunotherapeutic properties of Flt3-ligand in a murine breast cancer model. Cancer Res. 57:3511.
7. Braun, S. E., K. Chen, B. R. Blazar, P. J. Orchard, G. Sledge, M. J. Robertson, H. E. Broxmeyer, and K. Cornetta. 1999. Flt3 ligand antitumor activity in a murine breast cancer model: a comparison with granulocyte-macrophage colony-simulating factor and a potential mechanism of action. Hum. Gene Ther. 10:2141.
8. Colombo, M. P., G. Ferrari, A. Stoppacciaro, M. Parenza, M. Rodolfo, F. Mavilio, and G. Parmiani. 1991. Granulocyte colony-stimulating factor gene transfer suppresses tumorigenicity of a murine adenocarcinoma in vivo. J. Exp. Med. 173:889.
9. Mackensen, A., A. Lindemann, and R. Mertelsmann. 1997. Immunostimulatory cytokines in somatic cells and gene therapy of cancer. Cytokine Growth Factor Rev. 8:119.
10. Fearon, E. R., D. M. Pardoll, T. Itaya, P. Golumbek, H. I. Levitsky, J. W. Simons, H. Karasuyama, B. Vogelstein, and P. Frost. 1990. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 60:397.
11. Gansbacher, B., K. Zier, B. Daniels, K. Cronin, R. Bannerji, and E. Gilboa. 1990. Interleukin-2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J. Exp. Med. 172:1217.
12. Golumbek, P. T., A. J. Lazenby, H. I. Levitsky, L. M. Jaffee, H. Karasuyama, M. Baker, and D. M. Pardoll. 1991. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science 254:713.
13. Cui, J., T. Shin, T. Kawano, H. Sato, E. Kondo, I. Toura, Y. Kaneko, H. Koseki, M. Kanno, and M. Taniguchi. 1997. Requirement for Vα14 NKT cells in IL-12-mediated rejection of tumors. Science 278:1623.
14. Asher, A. L., J. J. Mule, A. Kasid, N. P. Restifo, J. C. Salo, C. M. Reichert, G. Jaffe, B. Fendly, M. Kriegler, and S. A. Rosenberg. 1991. Murine tumor cells transduced with the gene for tumor necrosis factor-α: evidence for paracrine immune effects of tumor necrosis factor against tumors. J. Immunol. 146:3327.
15. Rosenthal, F. M., K. Cronin, R. Bannerji, D. W. Golde, and B. Gansbacher. 1994. Augmentation of antitumor immunity by tumor cells transduced with a retroviral vector carrying the interleukin-2 and interferon-γ cDNAs. Blood 83:1289.
16. Mule, J. J., M. Custer, B. Averbook, J. C. Yang, J. S. Weber, D. V. Goeddel, S. A. Rosenberg, and T. J. Schall. 1996. RANTES secretion by gene-modified tumor cells results in loss of tumorigenicity in vivo: role of immune cell sub-populations. Hum. Gene Ther. 7:1545.
17. Laning, J., H. Kawasaki, E. Tanaka, Y. Luo, and M. E. Dorf. 1994. Inhibition of in vivo tumor growth by the β chemokine, TCA3. J. Immunol. 153:4625.
18. Nakashima, E., A. Oya, Y. Kubota, N. Kanada, R. Matsushita, K. Takeda, F. Ichimura, K. Kuno, N. Mukaida, K. Hirose, et al. 1996. A candidate for cancer gene therapy: MIP-1α gene transfer to an adenocarcinoma cell line reduced tumorigenicity and induced protective immunity in immunocompetent mice. Pharm. Res. 13:1896.
19. Dilloo, D., K. Bacon, W. Holden, W. Zhong, S. Burdach, A. Zlotnick, and M. Brenner. 1996. Combined chemokine and cytokine gene transfer enhances antitumor immunity. Nat. Med. 2:1090.
20. Rollins, B. J., and M. E. Sunday. 1991. Suppression of tumor formation in vivo by expression of the JE gene in malignant cells. Mol. Cell. Biol. 11:3125.
21. Huang, S., K. Xie, R. K. Singh, M. Gutman, and M. Bar-Eli. 1995. Suppression of tumor growth and metastasis of murine renal adenocarcinoma by syngeneic fibroblasts genetically engineered to secrete the JE/MCP-1 cytokine. J. Interferon Cytokine Res. 15:655.
22. Nishioka, Y., S. Yano, F. Fujiki, N. Nukaida, K. Matsushima, T. Tsuruo, and S. Sone. 1997. Combined therapy of multidrug-resistant human lung cancer with anti-P-glycoprotein antibody and monocyte chemoattractant protein-1 gene transduction: the possibility of immunological overcoming of multidrug resistance. Int. J. Cancer 71:179.
23. Bottazzi, B., S. Walter, D. Govoni, F. Colotta, and A. Mantovani. 1992. Monocyte chemotactic cytokine gene transfer modulates macrophage infiltration, growth, and susceptibility to IL-2 therapy of a murine melanoma. J. Immunol. 148:1280.
24. Nakajima, A., T. Kodama, S. Morimoto, M. Azuma, K. Takeda, H. Oshima, S. Yoshino, H. Yagita, and K. Okumura. 1998. Antitumor effect of CD40 ligand: elicitation of local and systemic antitumor responses by IL-12 and B7. J. Immunol. 161:1901.
25. + tumor cells are potent vaccines for stimulating tumor rejection in tumor-bearing mice. J. Exp. Med. 181: 619.
26. Broxmeyer, H. E., and C. H. Kim. 1999. Regulation of hematopoiesis in a sea of chemokine family members with a plethora of redundant activities. Exp. Hematol. 27:1113.
27. Broxmeyer, H. E., and C. H. Kim. 1999. Chemokines and hematopoiesis. In Chemokines and Cancer. R. B. J. Humana Press, Totowa, pp. 263-291.
28. Ngo, V. N., H. L. Tang, and J. G. Cyster. 1998. Epstein-Barr virus-induced molecule 1 ligand chemokine is expressed by dendritic cells in lymphoid tissues and strongly attracts T cells and activated B cells. J. Exp. Med. 188:181.
29. - NK cells and late stage lymphoid progenitors. Cell. Immunol. 193:226.
30. Kim, C. H., L. M. Pelus, J. R. White, E. Applebaum, K. Johanson, and H. E. Broxmeyer. 1998. CK β-11/macrophage inflammatory protein-3 β/EBI1-ligand chemokine is an efficacious chemoattractant for T and B cells. J. Immunol. 160:2418.
31. Kim, C. H., L. M. Pelus, J. R. White, and H. E. Broxmeyer. 1998. Differential chemotactic behavior of developing T cells in response to thymic chemokines. Blood 91:4434.
32. Dieu, M.-C., B. Vanbervliet, A. Vicari, J.-M. Bridon, E. Oldham, S. Ait-Yahia, F. Briere, A. Zlotnik, S. Lebecque, and C. Caux. 1998. Selective recruitment of immature and mature dendritic cells by distinct chemokines expressed in different anatomic sites. J. Exp. Med. 188:373.
33. Kim, C. H., L. M. Pelus, J. R. White, and H. E. Broxmeyer. 1998. Macrophage-inflammatory protein-3 β/EBI1-ligand chemokine/CK β-11, a CC chemokine, is a chemoattractant with a specificity for macrophage progenitors among myeloid progenitor cells. J. Immunol. 161:2580.
34. Kim, C. H., and H. E. Broxmeyer. 1999. Chemokines: signal lamps for trafficking of T and B cells for development and effector function. J. Leukocyte Biol. 65:6.
35. Yoshida, R., T. Imai, K. Hieshima, J. Kusuda, M. Baba, M. Kitaura, M. Nishimura, M. Kakizaki, H. Nomiyama, and O. Yoshie. 1997. Molecular cloning of a novel human CC chemokine EBI1-ligand chemokine that is a specific functional ligand for EBI1, CCR7. J. Biol. Chem. 272:13803.
36. Miller, A. D., and G. J. Rosman. 1989. Improved retroviral vectors for gene transfer and expression. BioTechniques 7:980.
37. Khoo, N., F. Chan, M. Saarloos, and P. Lala. 1992. Immunotherapy of mammary adenocarcinoma metastases in C3H/HeN mice with chronic administration of cyclooxygenase inhibitors alone or in combination with IL-2. Clin. Exp. Metastasis 10:239.
38. Saarloos, M., N. Khoo, and P. Lala. 1992. Effects of cancer immunotherapy with indomethacin and interleukin-2 on murine hematopoietic stem cells. Cancer Res. 52:6452.
39. Markowitz, D., S. Goff, and A. Bank. 1988. Construction and use of a safe and efficient amphotropic packaging cell line. Virology 167:400.
40. Markowitz, D., S. Goff, and A. Bank. 1988. A safe packaging line for gene transfer: separating viral genes on two different plasmids. J. Virol. 62:1120.
41. Sokal, R. R., and F. J. Rohlf. 1981. Biometry: The Principles and Practice of Statistics in Biological Research, 2nd Ed. W. H. Freeman and Company, San Francisco.
42. + T cells promptly produce interleukin 4 in response to in vivo challenge with anti-CD3. J. Exp. Med. 179: 1285.
43. Forster, R., A. Schubel, D. Breitfeld, E. Kremmer, I. Renner-Muller, E. Wolf, and M. Lipp. 1999. CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs. Cell 99:23.
44. + CD38 cells and maintains progenitor cells in vitro. Blood 87:3563.
45. Maraskovsky, E., K. Brasel, M. Teepe, E. R. Roux, S. D. Lyman, K. Shortman, and H. J. McKenna. 1996. Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell sub-populations identified. J. Exp. Med. 184:1953.
46. Drakes, M. L., L. Lu, V. M. Subbotin, and A. W. Thomson. 1997. In vivo administration of Flt3 ligand markedly stimulates generation of dendritic cell progenitors from mouse liver. J. Immunol. 159:4268.
47. Peron, J.-M., C. Esche, V. M. Subbotin, C. Maliszewski, M. T. Lotze, and M. R. Shurin. 1998. FLT3-ligand administration inhibits liver metastases: role of NK cells. J. Immunol. 161:6164.
48. Shaw, S. G., A. A. Maung, R. J. Steptoe, A. W. Thomson, and N. L. Vujanovic. 1998. Expansion of functional NK cells in multiple tissue compartments of mice treated with Flt3-ligand: implications for anti-cancer and anti-viral therapy. J. Immunol. 161:2817.
49. Singh, R. K., K. Berry, K. Matsushima, K. Yasumoto, and I. J. Fidler. 1993. Synergism between human monocyte chemotactic and activating factor and bacterial products for activation of tumoricidal properties in murine macrophages. J. Immunol. 151:2786.
50. + cells from multipotential murine bone marrow progenitors in stroma-free culture: definition f cytokine requirements and developmental intermediates. J. Exp. Med. 186:1609.
51. Tomura, M., W. G. Yu, H. J. Ahn, M. Yamashita, Y. F. Yang, S. Ono, T. Hamaoka, T. Kawano, M. Taniguchi, Y. Koezuka, and H. Fujiwara. 1999. A novel function of Vα14 + CD4 + NKT cells: stimulation of IL-12 production by antigen-presenting cells in the innate immune system. J. Immunol. 163:93.
52. Kitamura, H., K. Iwakabe, T. Yahata, S. Nishimura, A. Ohta, Y. Ohmi, M. Sato, K. Takeda, K. Okumura, L. Van Kaer, et al. 1999. The natural killer T (NKT) cell ligand α-galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expression on NKT cells. J. Exp. Med. 189:1121.
53. - T cells in mice and humans. J. Exp. Med. 180:1097.
54. + T cells by CD1-expressing cortical thymocytes. J. Exp. Med. 182:2091.
55. Taub, D. D., J. R. Ortaldo, S. M. Turcovski-Corrales, M. L. Key, D. L. Longo, and W. J. Murphy. 1996. β chemokines costimulate lymphocyte cytolysis, proliferation, and lymphokine production. J. Leukocyte Biol. 59:81.
56. Xu, L. L., M. K. Warren, W. L. Rose, W. Gong, and J. M. Wang. 1996. Human recombinant monocyte chemotactic protein and other c-c chemokines bind and induce directional migration of dendritic cells in vitro. J. Leukocyte Biol. 60:365.